Search

The author explains why the Australian government should consider replacing quadrivalent human papillomavirus (HPV) vaccines into bivalent vaccines. He argues that the claims of both the quadrivalent vaccine Garadasil from Merck and the bivalent vaccine Cervarix from GlaxoSmithKline (GSK) lies in the principle of the induction of neutralizing antibodies that can prevent the virus from damaging its target cell. He considers the argument of the cost effectiveness of quadrivalent HPV vaccine.